MRA Advisory Group Buys Shares of 23,652 Bristol Myers Squibb Company $BMY

Key Points

• MRA Advisory Group acquired 23,652 Bristol Myers Squibb shares in the second quarter, valued at approximately $1.36 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported strong quarterly results, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion, up 5.7% year over year.
• Analyst sentiment remains broadly positive but mixed: BMY has an overall “Moderate Buy” rating and an average price target of $66.06, while several firms recently downgraded the stock to Hold or Neutral. The company also offers a $0.63 quarterly dividend, representing a 3.9% annualized yield.

MRA Advisory Group bought a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 23,652 shares of the biopharmaceutical company's stock, valued at approximately $1,363,000.

Several other institutional investors and hedge funds also recently modified their holdings of BMY. Brighton Jones LLC raised its holdings in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock worth $1,116,000 after acquiring an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company's stock valued at $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank boosted its stake in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,277 shares during the last quarter. Marshall Wace LLP purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $221,000. Finally, Nebula Research & Development LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $405,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

A number of research firms have issued reports on BMY. Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday. They issued a "strong-buy" rating on the stock. UBS Group downgraded shares of Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a report on Wednesday. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a research report on Friday, July 31st. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Jefferies Financial Group lowered shares of Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of "Moderate Buy" and an average target price of $66.06.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades improve sentiment. Argus upgraded BMY to Buy, while Zacks raised the stock to a Rank #2 (Buy), citing improving earnings prospects. These recommendations may attract additional income- and value-oriented investors. Argus Upgrades Bristol Myers Squibb to Buy Bristol Myers Moves to Buy
• Positive Sentiment: Recent earnings exceeded expectations. Bristol Myers Squibb reported quarterly earnings of $2.04 per share versus the $1.60 consensus estimate, while revenue of $12.97 billion surpassed the $11.74 billion forecast. Revenue also grew 5.7% year over year, reinforcing the positive earnings narrative discussed on the company’s earnings call. Bristol Myers Squibb Q2 Earnings Call
• Positive Sentiment: Pipeline and research investments provide longer-term support. BMY is launching a real-world study examining luspatercept use in anemia care, while an expanded partnership with Schrödinger will deploy AI drug-discovery tools across BMS teams. These initiatives could improve evidence generation and help accelerate future medicines. Bristol Myers Squibb Tracks Luspatercept Use Schrödinger and BMS Expand Partnership
• Neutral Sentiment: Broader optimism around potential biotech and pharmaceutical catalysts may support sector sentiment, but the cited drug-development opportunities are not specific to BMY. New Drugs Could Fuel Pharma Stock Gains

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $64.63 on Friday. The business's 50-day moving average price is $58.71 and its 200 day moving average price is $58.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.10. The company has a market capitalization of $132.02 billion, a PE ratio of 14.24, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to analysts' expectations of $11.74 billion. During the same quarter in the previous year, the business earned $1.46 EPS. The firm's revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source